| |
|
|
| |
|
|
| |
HUM-MOLGEN
-> Events
-> Courses and Workshops |
|
|
| |
Imaging in Clinical Trials: Considerations from FDA and EMEA | |
| |
August 16, 2006 |
|
|
| |
|
|
| |
|
|
|
Drug Information Association, Online
Sep 22 2006
This innovative webinar will explore several imaging-related issues drawn from FDA’s Critical Path Opportunities List, identify opportunities for collaboration among FDA, EMEA and other stakeholders, and focus on three important elements of medical imaging in clinical trials, including:
•Imaging biomarker validation
•Standardization, charters, and imaging submissions
•EU experiences and expectations for imaging in drug development.
|
|
|
|
|
|
|
|
Organized by:
|
|
Drug Information Association |
|
|
Invited Speakers:
|
|
CRAIG H. LIPSET, MPH
Associate Vice President
Program Management
Adnexus TherapeuticsGEORGE Q. MILLS, MD
Director, Medical Imaging and
Radiopharmaceutical Drug Products
FDA JEAN--NOEL TALBOT, MD, PHD
University Professor
Chairman of the Scientific Advisory Group
on Diagnostic Agents of EMEA
Head of the Nuclear Medicine Department
and PET Centre at University Hospital Tenon
Assistance Publique—Hôpitaux de Paris, France
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
-
|
|
|
|
|
|
|
|
Registration:
|
|
http://www.diahome.org/product/12122/06242.pdf
|
|
|
E-mail:
|
|
dia@diahome.org
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp,
Frank S.
Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved.
Liability, Copyright and Imprint. |
|